ArticleNeural regeneration research2016
The neuroprotective effects of the anti-diabetic drug linagliptin against Aβ-induced neurotoxicity.
Article in Neural regeneration research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Linagliptin, a Selective DPP-4 Inhibitor, Attenuates Ketamine- and Diazepam-Induced Deficits in Passive Avoidance Performance in Mice.Brain sciences · 2026Article
- Exploring the Anxiolytic Potential of NPY by a Dipeptidyl Peptidase-IV Inhibitor in an Animal Model of PTSD.The international journal of neuropsychopharmacology · 2024Article
- GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review.Current topics in medicinal chemistry · 2024Review
- Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia.Current diabetes reviews · 2024Review
- In Silico Exploration of Metabolically Active Peptides as Potential Therapeutic Agents against Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2023Article
- Low-Carbohydrate High-Fat Diet: A SWOC Analysis.Metabolites · 2022Review
- Omarigliptin Mitigates 6-Hydroxydopamine- or Rotenone-Induced Oxidative Toxicity in PC12 Cells by Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Actions.Antioxidants (Basel, Switzerland) · 2022Article
- Protective effect of alogliptin against cyclophosphamide-induced lung toxicity in rats: Impact on PI3K/Akt/FoxO1 pathway and downstream inflammatory cascades.Cell and tissue research · 2022Article
- Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study.Frontiers in pharmacology · 2022Article
- Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia.Journal of experimental pharmacology · 2022Review
- Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with AMolecules (Basel, Switzerland) · 2021Article
- Alogliptin: a novel approach against cyclophosphamide-induced hepatic injury via modulating SIRT1/FoxO1 pathway.Toxicology research · 2020Article
- Article
- Preventive Effects of Dulaglutide on Disuse Muscle Atrophy Through Inhibition of Inflammation and Apoptosis by Induction of Hsp72 Expression.Frontiers in pharmacology · 2020Article
- Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.Neural regeneration research · 2019Review
- Antidiabetic treatment on memory and spatial learning: From the pancreas to the neuron.World journal of diabetes · 2019Review
- Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.Scientific reports · 2018Article
- Cellular Stresses and Stress Responses in the Pathogenesis of Insulin Resistance.Oxidative medicine and cellular longevity · 2018Review
- Tackling dipeptidyl peptidase IV in neurological disorders.Neural regeneration research · 2018Review
- Mevastatin promotes neuronal survival against Aβ-induced neurotoxicity through AMPK activation.Metabolic brain disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.